Top 50 Life Science Startup Investors in France in September 2025

Investor	Life Science France investments
Bpifrance	13
Kurma Partners	8
Omnes Capital	6
Seventure Partners	5
Sofinnova Partners	5
Paca Investissement	4
Idinvest Partners	4
Blue Horizon Corporation	3
Boehringer Ingelheim Venture Fund	3
Karista	3
Galia Gestion	3
AdBio partners	3
JDRF T1D Fund	2
Sylvain Zimmer	2
Alexandria Venture Investments	2
Polytechnique Ventures	2
Partech	2
Air Street Capital	2
Beyond Impact	2
Invus	2
Heartcore Capital	2
Andrew Nutter	2
Social Starts	2
AQUITI Gestion	2
Kinled Holding	2
XAnge	2
Advent Life Sciences	2
Siparex Groupe	2
Point Nine	2
Angels Santé	2
IRDI SORIDEC Gestion	2
Thia Ventures	2
Eutopia VC	2
WiSEED	2
Horizons Ventures	2
Sofimac Investment Managers	2
Resiliance	1
Credit Agricole CIB	1
InnoBio Fund	1
INRA	1
Crédit Mutuel Innovation	1
Societe Generale Asset Management	1
Matignon Technologies	1
AxLR	1
CIC Finance	1
Eurobail	1
NACO	1
Credit Mutuel	1
Lundbeckfonden Ventures	1
IRDI	1

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Investment focus

Software, Information Technology, Health Care
Seed, Funding Round, Series A
France, United States, Switzerland

Portfolio highlights

AUSTRAL Dx — AUSTRAL Dx is developing a new imaging technique based on airborne ultrasounds in order to map the vibrations coming from the lungs. The company was founded in 2021 and is based in Paris.
Aircap — Aircap revolutionizes investment with a banking platform dedicated to investors.
Electra — Electra is a platform that provides Charging stations Ultrafast for electric vehicles.

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Seed, Series B
France, Switzerland, Spain

Portfolio highlights

DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.

Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.

Investment focus

Biotechnology, Software, Health Care
Series A, Funding Round, Series B
France, Germany, United States

Portfolio highlights

Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
VSORA — VSORA provides high performance companion solutions combining AI and signal processing to enable autonomous driving and ADAS
Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Investment focus

Biotechnology, Health Care, Software
Series A, Funding Round, Series B
France, United States, Germany

Portfolio highlights

ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
Reelevant — Only 1 out of 10 people interact with marketing messages. Content is the bottleneck of personalization, not data. Personalization doesn't work because data are used to create targeted campaigns. Data must be used to create content because content creates interactions and drive conversion.Why: create content for people, not for campaigns(visual is the key to emotions) How: on-demand, when the user request, at the opening/reading/exposure (Pull content vs Push marketing) What: end-to-end widgets solutions like Live content, Individualization, Content Automation, Optimization, etc.Our visual content platform accelerates revenue, creates content based on any data (behavioral, contextual, etc.) created on the fly at the moment of exposure (on any channel (email, web, push notifications, in-app messages, etc.). We take advantage of existing data sources, nothing to create, we supercharge your marketing stack. Our data-driven Content Engine translates data from any source into on-demand visual content in milliseconds for each people.We believe in a new way of thinking about messages by shifting the paradigm of push marketing to transform any data into on-demand visual content. One unique content is created for each people on the fly at the moment people decide to read them (pull content), instead of when marketers decide to create them (push marketing).People are not data points, people don't buy products, they buy emotions. On-demand visual content is the new game!
Seaweed Concept — Seaweed Concept is a marine biotechnology company, that focuses on the innovative utilization of seaweed to provide high-quality ingredients to various industrial sectors

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
One Biosciences — One Biosciences unlocks routine analysis of tumor heterogeneity through AI-powered single-cell technologies, transforming precision medicine.
Galvanize Therapeutics — Galvanize Therapeutics is an energy-based medical device technology that provides therapeutic products and services to deliver healthcare solutions. The company aims to become the global leader in delivering medical technology innovations that drive biological processes to treat a range of diseases, starting with treating chronic bronchitissymptoms, cardiac arrhythmias, and solid tumors.It was formed by Apple Tree Partners in 2022.

Paca Investissement is specializes in investing in startups and developmental stages. The fund invests in the Provence-Alpes-Côte d'Azur (PACA) region.

Investment focus

Software, Internet, Manufacturing
Seed, Funding Round, Series A
France

Portfolio highlights

GANGZ — Gangz is the first digital platform for talent recruitment: Models, hosts, extras and actors.
SailEazy — The SailEazy community offers all sailing enthusiasts the choice of freedom. A shared professional fleet, bases between the Atlantic and the Mediterranean ... discover a disruptive and innovative way of navigation. Throughout the year, 7 days / 7 and 24 hours a day, you can book and discover the high-performance sailboats of a professionalfleet, entirely managed by SailEazy. Subscriber, or punctual browser, autonomous or not, you have the choice. You freely determine your niche of reservation, without constraint time or duration, you choose your base of departure and your sailboat, according to your program (short exit, cruise, regatta, coastal, wide ...). Hourly pricing includes a 360 ° service keychain beyond the cost of the lease, including insurance, fuel, cleaning and equipment. Compulsive veiled, expert or contemplative, all members of the community have their way of navigating.
C4Diagnostics — C4Diagnostics developed a fast, reliable detection of microorganisms. Our Click-chemistry technology is at the core of our portfolio of diagnostic tests.

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
France, United States, Spain

Portfolio highlights

Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
StarTower — StarTower is a resource company built specifically for fully decentralized physical infrastructure and shared interaction. Based on the exclusive RIP encryption technology, StarTower realizes the interactive sharing of multiple resources with zero loss on mobile devices, thereby providing efficient resource transmission for terminal facilities. Itprovides more efficient, secure and reliable solutions in the fields of Internet of Things, smart cities, industrial automation, healthcare, etc.
Stilla Technologies — Stilla Technologies is taking digital PCR to a whole new level with a unique 6-color target detection capability

Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.

Investment focus

Food and Beverage, Food Processing, Biotechnology
Seed, Series A, Pre-Seed
United States, United Kingdom, Germany

Portfolio highlights

WOW EARN — Discover WOW EARN, the all-in-one Web3 app with crypto mining, multi-chain wallet, staking NFTs, and marketplace dApps. Join the global Web3 community today.
EV Biotech — We design and optimise your precision fermentation strains and processes, tailored to your success.
foodforecast — AI supported solution to reduce food waste.

Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.

Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.

Investment focus

Software, Biotechnology, Health Care
Seed, Series A, Series B
France, United States, Finland

Portfolio highlights

Deemea — Deemea is a collaborative AI platform that connects and provides services for the analysis of medical data for physicians. It uses its expertise in clinical research, data science, and software development to help healthcare professionals.
Sitowie — Sitowie develops SaaS technology and tools to understand the degradation of buildings.
Brightflow — Brightflow operates as a medical device startup.

Galia Gestion is a private equity and venture capital firm. GALIA Gestion is a “management company” approved by the AMF, with majority shareholder Alliance Entreprendre.

Investment focus

Software, Manufacturing, Biotechnology
Funding Round, Series A, Seed
France, United States

Portfolio highlights

Wizaly — Wizaly's ambition is to help advertisers understand the impact of their online & offline marketing channels across all conversions, helping clients improve the ROI of their marketing budgets by up to 30%.The Wizaly platform applies its algorithmic attribution technology to provide a holistic and unbiased vision of campaigns performancestogether with actionable optimization recommendations.
Agenium — Agenium offers career perspectives in an international and tech environment. They offer this through the specific expertise of their business units. They offer solutions to the business and of the defense, industry, and space sectors.
Germitec SAS — Germitec is a world leader in UV-C high-level disinfection. Fast, safe, chemical-free, one-button UV-C high-level disinfection for ultrasound probes.

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Funding Round
France, Spain, Belgium

Portfolio highlights

Cephagenix — Cephagenix focuses on identifying and developing new, effective migraine therapies.
Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
United States, France, Italy

Portfolio highlights

vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
Eledon Pharmaceuticals — Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Cour Pharmaceuticals Development — Reprogramming the immune system. Restoring lives.At COUR, we develop targeted therapies that incite calm within the immune system and help restore the healt ...

Sylvain is a French software developer turned entrepreneur, conference organizer and angel investor.

Investment focus

Software, Financial Services, SaaS
Seed, Pre-Seed, Angel
France, United States, United Kingdom

Portfolio highlights

GOURMEY — We create sustainable cultivated meat delights for an uncompromising and conscious generation.
Waldo — The codeless way to quickly build a comprehensive test suite for teams who don't compromise on speed and quality.
TOTEM — A Totem is a place of sharing and conviviality in your office. This is an opportunity for your colleagues to get to know each other better, celebrate victories and defeats together, and build a solid culture.

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Canada, France

Portfolio highlights

Remedy Plan Therapeutics — Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.
Dispatch Bio — Dispatch Bio helps create a world where all cancer patients can be cured.
GeneCentric Therapeutics — GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Polytechnique Ventures support entrepreneurs from the School's ecosystem.

Investment focus

Biotechnology, Information Technology, Life Science
Seed, Series A, Funding Round
France, United Kingdom, United States

Portfolio highlights

bYoRNA — bYoRNA is a French biotechnology company specializing in the cost-efficient, scalable bioproduction of high-quality therapeutic messenger RNA (mRNA) using engineered eukaryotic cells, particularly recombinant yeast. Their disruptive platform enables the production of long, humanized mRNA with lower immunogenicity and higher integrity compared totraditional in vitro enzymatic synthesis. This technology aims to mass produce mRNA for gene therapies, cancer vaccines, and infectious disease vaccines at a fraction of current costs, making mRNA therapeutics more accessible globally.
mirSense — mirSense technology is a developer and manufacturer of a new generation of ultra-compact gas sensors designed to offer lasers for the medium infrared. The company's Industrial Quantum Cascade Laser (QCL) and QCL-based spectrometer modules provide very low detection levels for the control of gas emissions, detection of dangerous substances orthe analysis of biological samples, enabling industries and defense sectors to get affordable quantum cascade lasers.
One Biosciences — One Biosciences unlocks routine analysis of tumor heterogeneity through AI-powered single-cell technologies, transforming precision medicine.

Partech is a global venture capital firm with offices in San Francisco, Paris, Berlin and Dakar. Partech invests in Internet and information technology startups at seed, venture and growth stages.

Investment focus

Software, E-Commerce, SaaS
Series A, Seed, Series B
United States, France, Germany

Portfolio highlights

Alpic — Alpic's all-in-one cloud platform provides the infrastructure and tools to turn your product into an AI-native experience. Build, deploy and monitor your MCP servers at scale easily, we'll handle the rest.
Exein — The firmware security software and middleware can be injected like a vaccine in the hardware and aims to defend it from inside, working directly into the firmware at a lower level.
Makersite — AI, data and apps for procurement, product design and expert teams to make faster sustainable product and supply chain decisions, at scale.

Air Street Capital invests in AI-first companies.

Investment focus

Artificial Intelligence, Machine Learning, Biotechnology
Seed, Series A, Pre-Seed
United States, United Kingdom, Canada

Portfolio highlights

Sereact — Discover the world's easiest pick and place automation solution. Significant cost savings, productive 24/7, deployment in one day and no training required.
Fern Labs — Deploying agents at the scale of real world problems
Hedera Dx — A diagnostics platform that makes liquid biopsies a reality in cancer care

Beyond Impact is your trusted Managed Service Provider (MSP), delivering tailored IT solutions like managed IT services, cybersecurity, cloud computing, IT help desk support, and data backup. Our expert team aligns your IT with business goals, providing proactive monitoring and network security. Contact us today to streamline your IT operations for a secure, agile, and future-ready business. Beyond Impact: Empowering your IT success.

Investment focus

Food and Beverage, News, Seafood
Seed, Series A, Pre-Seed
France, Canada, Singapore

Portfolio highlights

GOURMEY — We create sustainable cultivated meat delights for an uncompromising and conscious generation.
Nowadays — The Nowadays nugget is made with just 7 simple, plant-based ingredients.
SEAFOOD REBOOT — Seafood Reboot's ambition is to promote worldwide best-in-class Fish substitutes from micro-algae for natural, healthy, sustainable food and to preserve marine wildlife.

Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic approach. Due to their unique structure, they have a great deal of flexibility in the types of companies and situations where they can get involved.They know that real transformation takes time and that it is nevera straight line. They fully align their incentives with their partners and have the wherewithal and long-term commitment to see through any bumps along the way.They have been successfully empowering owner-managers since 1985. They have been reinvesting the same pool of money from the same group of European families (through their Artal investment vehicle) since their founding. Today they manage over $4 billion in an evergreen fund and work out of offices in New York, London, Paris and Hong Kong.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
United States, France, China

Portfolio highlights

One Biosciences — One Biosciences unlocks routine analysis of tumor heterogeneity through AI-powered single-cell technologies, transforming precision medicine.
GenSight Biologics — GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.
Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.

Heartcore Capital invests in companies re-enchanting the world through technology.

Investment focus

Software, FinTech, Artificial Intelligence
Seed, Series A, Series B
Denmark, United States, Germany

Portfolio highlights

PhaseTree — Materials design simulation company - PhaseTree ApS
Veda — Veda is the largest vault infrastructure platform in DeFi, enabling institutions to launch and manage onchain financial products at scale.
Superform Labs — THE UNIVERSAL INTERFACE FOR YIELD IS FORMING

Andrew Nutter is a Co-Founder at Gama. He attended Stanford University.

Investment focus

Software, SaaS, Biotechnology
Seed, Pre-Seed, Funding Round
France, United Kingdom, United States

Portfolio highlights

Yavin — Yavin provides modern point-of-sale solutions for European merchants
Gama — Thanks to cheap, reliable and scalable solar sails, we are redefining deep space access.
EV Biotech — We design and optimise your precision fermentation strains and processes, tailored to your success.

Social Starts is a $60M+ venture capital partnership with a uniquely data-driven approach to investing in moment-of-inception and Series A financing rounds.

Investment focus

Software, Health Care, Artificial Intelligence
Seed, Series A, Funding Round
United States, Germany, United Kingdom

Portfolio highlights

Hey Jane — Get safe, effective and affordable abortion pills delivered fast to your home. Hey Jane is the first digital abortion clinic, connecting you to licensed providers in your state through telemedicine.
Mae Health — Mae is a maternal health platform that connects expectant mothers with critical resources to drive positive pregnancy outcomes.
Wayfinder Biosciences — We design RNA for next generation biomanufacturing and smart therapeutics.

Floated in 1998, thanks to the local authority "Conseil Régional d’Aquitaine" and the "Caisse des dépôts", our venture, growth and LBO funds (Aquitaine Amorçage, ACI, Aqui-Invest) now benefit from the support of public and private influential shareholders and sponsors.Up to now, AQUITI GESTION has invested in more than 200operations contributing to the creation and development of about 150 companies and thousands of jobs.Currently, ACI and Aqui-Invest manage a portfolio gathering 50 companies which revenues scale from 0 € (early stage) to 30 M€.

Investment focus

Biotechnology, Software, Manufacturing
Funding Round, Series A, Seed
France, United States

Portfolio highlights

Speeral — Speeral is a technological solution for user to access second-hand market and products.
Aquassay — Aquassay assists you with improving the industrial and environmental performance of all your water usage (supply, production, discharge).
Materrup — Materrup produces low-carbon earth concrete for construction and urban development. Materrup construction solutions meet the requirements of future RE2020 regulations and the urgent need to reduce the carbon footprint of the construction industry.

Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.

Investment focus

Biotechnology, Health Care, Financial Services
Seed, Funding Round, Series A
United Kingdom, United States, Switzerland

Portfolio highlights

Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.

XAnge is a Franco-German team of venture capital investors that manages €450 million and invests in digital, deeptech, and impact startups.It is the innovation brand of the Siparex group, a major player in French private equity. XAnge is a key European investor in early-stage startups and is looking for game-changing startups and entrepreneurswho rock the code[s].The Paris, Ile-de-France-located company was founded in 2004.

Investment focus

Software, Information Technology, SaaS
Series A, Seed, Series B
France, Germany, Belgium

Portfolio highlights

Animaj — Explore the future of storytelling where AI meets creativity at Animaj Lab. Join us on a journey to revolutionize kids' entertainment, crafting captivating content that keeps the digital-first generation engaged and inspired.
Ensweet — Ensweet is a telemedicine platform intended to offer telerehabilitation services to patients. They offer equipment so that everyone can exercise whenever possible, enabling patients to have accessible rehabilitation.
Diagnoly — Diagnoly provides AI-powered ultrasound assistant that enhances fetal screenings with real-time analysis, instant insights, and zero workflow disruption.

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
United States, United Kingdom, France

Portfolio highlights

Cyted — Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use AI and novel biomarkers to improve patient outcomes.
Glycomine — We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.
Relief Cardiovascular — Relief Cardiovascular is an inQB8 medical technologies portfolio company developing a revolutionary smart implant to decongest heart failure patients.

Siparex, France,s first multi-sectoral private equity investment company, is founded in Lyon.It was a start-up at a time when the spirit of enterprise was flagging. It emerged in one of France's regions, listed the shares of the original company one of its main vehicles on the stock market, grew internationally, and has become one of theindependent groups in its line of business in the space of 30 years.

Investment focus

Manufacturing, Software, Information Technology
Private Equity, Funding Round, Seed
France, United States, Italy

Portfolio highlights

E-Recycle — E-Recycle is an online and offline store that specializes in recycling used high-tech products such as mobile phones, tablets, and PCs.
NeoPhotonics — NeoPhotonics design and manufacture advanced hybrid photonic integrated optoelectronic devices for ultra-fast communications networks, including optical components
Ekoscan Integrity — Ekoscan Integrity is an innovative solution for the integrity and sustainability of industrial products through the implementation of innovative technology.

Point Nine Capital is a Berlin-based venture capital firm focused exclusively on early-stage Internet investments in areas like Software-as-a-Service (SaaS), online marketplaces, and mobile.The fund and its managers, Pawel Chudzinski and Christoph Janz have backed a number of highly successful Internet companies such as Delivery Hero, Clio,Shiftplanning, Vend, Typeform, and Zendesk from their earliest stages.

Investment focus

Software, SaaS, Internet
Seed, Series A, Series B
Germany, United States, France

Portfolio highlights

Attio — Unlock your team's true potential with Attio, the data-driven CRM for modern teams. Manage everything from sales leads through to recruitment pipelines.
sensmore — Equip your machinery with autonomy built for the harshest conditions. Enhance safety, reduce costs, and increase efficiency with our advanced radar technology.
Rerun — Multimodal log handling and visualization for spatial and embodied AI. Managed infrastructure to ingest, store, analyze, and stream data at scale with built-in visual debugging. Fast, flexible, and easy to use.

Angels Santé is the leading French Business Angel Network solely dedicated to Healthcare investments.

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Funding Round, Angel
France, India, United States

Portfolio highlights

Ensweet — Ensweet is a telemedicine platform intended to offer telerehabilitation services to patients. They offer equipment so that everyone can exercise whenever possible, enabling patients to have accessible rehabilitation.
AUSTRAL Dx — AUSTRAL Dx is developing a new imaging technique based on airborne ultrasounds in order to map the vibrations coming from the lungs. The company was founded in 2021 and is based in Paris.
MB Therapeutics — MB Therapeutics is a pharmaceutical firm that provides patient-centric solutions for developing and producing tailored medicines.

IRDI SORIDEC Gestion is a portfolio management company that supports startups, SMEs, and ETIs in the greater South-West of France with equity capital at all stages of development.

Investment focus

Software, Biotechnology, Manufacturing
Seed, Series A, Funding Round
France, Brazil, Singapore

Portfolio highlights

bYoRNA — bYoRNA is a French biotechnology company specializing in the cost-efficient, scalable bioproduction of high-quality therapeutic messenger RNA (mRNA) using engineered eukaryotic cells, particularly recombinant yeast. Their disruptive platform enables the production of long, humanized mRNA with lower immunogenicity and higher integrity compared totraditional in vitro enzymatic synthesis. This technology aims to mass produce mRNA for gene therapies, cancer vaccines, and infectious disease vaccines at a fraction of current costs, making mRNA therapeutics more accessible globally.
FEEDAE — Feedae uses AI-augmented dialog analysis to boost sales and customer service teams' performance.
Greenphage — Greenphage develops bacteriophage-based methods to address bacterial infections and contaminations in human, animal, and plant health. It uses bacteriophages to create alternatives to antibacterial treatments. The company conducts laboratory research on phage studies, molecular virology, and microbiology. It also works with research institutions tosupport its phage therapy efforts.

WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team

Investment focus

Biotechnology, Food and Beverage, Health Care
Series A, Seed, Series B
United States, France, Denmark

Portfolio highlights

EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
Protealis — Sustainable plant proteins for Europe
Switch Bioworks — Switch Bioworks engineers symbiotic microbes to produce sustainable nitrogen fertilizer under the control of precise genetic circuits.

Eutopia is a fund for consumer startups. We back founders who are rethinking the way we eat, shop, sleep and feel. We are backing 26 startups

Investment focus

Retail, E-Commerce, Food and Beverage
Seed, Series A, Funding Round
France, Belgium, Denmark

Portfolio highlights

GOURMEY — We create sustainable cultivated meat delights for an uncompromising and conscious generation.
Bastille — Bastille is a brand of urban bicycles. The Astir brand is synonymous with folding bicycles. The primary quality constraint Bastille, a British designer, aims to create a folding motorcycle with standard wheels rather than the mini 16-inch wheels that are traditionally associated with folding bikes.
SPRiNG Collective — SPRiNG is a consumer goods company that offers clean and efficient laundry and cleaning products, delivered in a 100% plastic-free box and directly in the mailbox. The company is headquartered in Paris, Ile-de-France, France by Philippe Cantet, Laure Favre, and Ben Guerville in 2017.

Wiseed is a crowdfunding platform that enables its users to invest in SMEs and enterprises. The platform offers investments for startups, real-estate firms, social innovation and renewable energy projects, and agriculture firms. It was founded in 2008 by Nicolas Seres and Thomas Merquiol and is based in Toulouse.

Investment focus

Software, Manufacturing, Biotechnology
Seed, Funding Round, Equity Crowdfunding
France

Portfolio highlights

Leasi — Leasi delivers a forward-thinking rental and resource management system for companies that engage in internal or external distribution of machinery. This is achieved through an ecosystem that emphasizes the excessive use of data and datasharing, with a focus on user experience. Our goal is to create a simpler, more streamlined, and more efficientworkday for industry players by leveraging the power of data and collaboration within the ecosystem to ultimately reduce emissions, increase efficiency and enhance profitability.
Aéronde — The Aéronde is an innovative electric airship with a toroidal shape (giant donut) of 15 meters in diameter, designed to offer a silent, energy-efficient flight with very low environmental impact. Inflated with approximately 400 m³ of helium, it can carry up to two people and equipment, with a payload of 200 kg .
Vaxinano — Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder.

Investing in the deep science and technology that can propel humanity towards a radically better future.

Investment focus

Biotechnology, Artificial Intelligence, Software
Series A, Series B, Seed
United States, United Kingdom, Canada

Portfolio highlights

Xampla — Xampla's natural plant polymer technology is the innovative technology powering materials to change the world with plastic-free replacements and more.
Harrison.ai — And a thirst for knowledge meets a passion for a better world.A world where people are cared for by people, medical data analysis is done at scale,
Owlstone Medical — Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease, and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novelnon-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA Breath Sampler ensures a reliable collection of breath samples. The volatile organic compounds (VOCs) present in the breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by the therapeutic response. The company also Breath Biopsy products and services to academic, clinical, and pharma partners who want to develop breath-based diagnostics for their own applications.

Acteur incontournable du capital risque de proximité, SOFIMAC PARTNERS accompagne depuis maintenant plus de 30 ans les PME régionales dans le financement de leur développement à moyen / long terme. Répondant à la problématique de sous capitalisation des PME françaises, SOFIMAC PARTNERS intervient en fonds propres aux côtés des chefsd’entreprises quelle que soit leur problématique : Création, Développement, Transmission. Gérant 200 M€ d’actifs au travers de 16 fonds (FCPR, FCPI, SCR, FIP,…), notre groupe réalise ses investissements sur une grande variété de secteurs, couvrant aussi bien les activités traditionnelles que technologiques (chimie verte, éolien, chaudronnerie aéronautique, e-commerce, édition de logiciel, médecine nucléaire etc…)

Investment focus

Biotechnology, Health Care, Manufacturing
Funding Round, Seed, Series A
France, Italy, Austria

Portfolio highlights

Ultrawatt — Ultrawatt is a mission-driven startup to improve urban architecture while making a beneficial social and environmental effect.
Mob-Energy — Mob-Energy is a privately held company specializing in the development of mobile and innovative charging solutions. It designs autonomous charging robots capable of moving energy where it is needed, optimizing the site's existing infrastructure. The company was founded in 2018 and is headquartered in Villeurbanne, Auvergne-Rhône-Alpes.
Snowleader — Votre boutique en ligne (qui sent bon le reblochon) spécialiste des sports d’hiver, outdoor et street.

Resilience Consulting offers talent, innovation, marketing, and performance improvement services to small and medium-sized businesses, they assist businesses in boosting growth, cutting expenses, and increasing engagement.

Investment focus

Life Science, Biotechnology, Waste Management
Seed
France

Portfolio highlights

Dionymer — dionymer creates endless opportunities for a multitude of industries. Replacing petrochemical polymers with a circular and biodegradable alternative.

Crédit Agricole CIB specialises in the businesses of capital markets and investment and corporate banking.

Investment focus

Energy, Solar, Renewable Energy
Debt Financing, Series A, Post-IPO Debt
France, United States, United Kingdom

Portfolio highlights

IONITY — IONITY makes long-distance travel with electric vehicles an enjoyable experience.
CoreWeave — CoreWeave provides flexible compute services and products to empower innovators. The company provides GPU accelerated compute solutions to the CGI and machine learning industries. Backed by quality hardware and systems management infrastructure, CoreWeave is built to help clients scale and adapt to evolving compute requirements at industry leadingeconomics.
Lightsource bp — Lightsource bp is a global leader in the development and management of utility-scale onshore renewable and energy storage solutions.

InnoBio is a French venture capital fund of €140 million, managed by CDC Enterprises (www.cdcentreprises.fr) and for 37 per cent subscribed by the FSI and leading international pharmaceutical companies in France. The fund makes direct equity and quasi-equity investments in companies that provide innovative technological products and services in thehealthcare market.

Investment focus

Biotechnology, Therapeutics, Health Care
Funding Round, Series A, Series C
France, United States

Portfolio highlights

Advicenne — Specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and neurology.
Millendo Therapeutics — Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need.
AlgoTherapeutix — AlgoTherapeutix is the operator of a biotechnology company designed to develop topical treatments for complex pain.

INRA is Europe’s top agricultural research institute and the world’s number two centre for the agricultural sciences. Its scientists are working towards solutions for society’s major challenges.

Investment focus

Biopharma, Health Care, Biotechnology
Seed, Series A
France

Portfolio highlights

ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
Exeliom — Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France.

Crédit Mutuel Innovation is the evergreen venture capital entity of Crédit Mutuel Equity (€3.5 billion in capital). We invest €1-20M in life science, digital and deeptech companies from seed to growth stages.We help bold and ambitious entrepreneurs to develop their strong growth potential with our worldwide enterprise ecosystem (our 350+portfolio companies, our abroad subsidiaries, 150+ largest global corporates and the best-in-class experts). Because it takes more than 5 years to build a Unicorn, we invest our own equity and ensure durable partnerships with visionary leaders.Today, the 350 companies in which we have invested generate a cumulative annual turnover of €50bn and create more than 250,000 jobs.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Series A, Series B
France, United States, Canada

Portfolio highlights

UroMems — The device is developing an active implantable medical device based on the cutting edge technologyl in the field of embedded systems and micro-technologies for the development of its products.
Planity — Planity, a platform that allows you to book an appointment with a professional in the beauty sector in a few clicks and quickly find a hair salon, beauty institute, barber near you
Latitude — Venture Orbital Systems provides a tailor-made service for NanoSat & CubeSat operators.

SGAM AI is a leading institutional player in Alternative Investment Management. SGAM AI successfully mixes the cultures of asset management and capital markets. They are client driven and institutional, like an asset manager. Their approach of each market is entrepreneurial and financial, like an investment bank. They offer the widest coverage ofAlternative Investment classes. Their size and profitability allow long term investments and credibility. They have the ability to offer solutions, not only products. SG Group's strengths are brought to the Alternative Investment's industry. They benefit from SG Group's long term commitment in Alternative Investments. They use the processes ans resources of SGAM Group (rated M2 by Fitch).

Investment focus

Biotechnology, Software, Health Care
Series B, Funding Round, Series A
France, United States, Germany

Portfolio highlights

Augure — Improve your brand performance with Launchmetrics' leading software solutions for fashion, lifestyle and beauty brands
Force-A — FORCE-A designs, produces, and sells optical sensors for the assessment of physiological and health status of crops. It offers crop sensors for nondestructive assessment of leaf polyphenolics. The company also provides multiparameter noncontact sensors-based on leaves or fruits, and berries autofluorescence measurements. Its multiparameternoncontact sensor provides inputs for decision support systems for a range of crops, including fertilisation needs, weed infestation, crop diseases, and crop yield and quality forecast. The company was founded in 2004 and is based in Orsay, France.
METRIXWARE — Metrixware has, since 1995, been providing software maintenance & quality management solutions to CIOs and IT professionals through its System Code range of application management tools. The company provides global organizations with information, indicators and diagnostic to streamline decision making and implement best practice and compliancestandards.

Matignon Technologies is a euro 50 M closed-end venture capital fund dedicated to investments in unlisted innovative, early-stage companies specialized in high technologies with strong growth potential. The Fund invests as a minority shareholder with a stake comprised between euro 0.5 M and 3.0 M euro. Subscriptions were closed in September 2000and the Fund has a lifespan of six years.

Investment focus

Medical, Biotechnology, Medical Device
Series A, Series B, Funding Round
United States, France

Portfolio highlights

Gentis — Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine. The company's patented product is DiscCell, an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material that augments or replaces the diseased nucleus pulposus of the spinal disc.Gentis wasfounded on 2000 and is headquartered in Wayne, Pennsylvania.
Alveolus — Alveolus is a leader in the emerging field of non-vascular interventional stenting through next generation stent technology.
Arterial Remodeling Technologies — Arterial Remodeling Technologies SA engages in developing bioresorbable peripheral and coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The company was founded in 2002 and is based in Noisy le Roi, France.

AxLR specializes in the assistance of commercialization and academic research maturity-based innovative projects.

Investment focus

Life Science, Biotechnology
Pre-Seed
France

Portfolio highlights

Ingraalys — Ingraalys studies genomic and cellular plasticity during development and aging. Exploring the limitations of this plasticity prompted her to investigate the potential reversibility of cellular aging.

CIC Finance is a firm that focuses on provided loan opportunities to individuals and businesses.

Investment focus

Health Care, Life Science, Therapeutics
Funding Round
France

Portfolio highlights

Polyplus-transfection — Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services.

Eurobail is a specialized training company that works in the real estate, banking, and insurance industries.

Investment focus

Health Care, Life Science, Clinical Trials
Series A
France

Portfolio highlights

DocCity — DocCity LifeSciences creates and provides outstanding spaces to house cutting-edge healthcare businesses. DocCity provides clinicians with state-of-the-art, fully furnished health spaces with roomy, well-lit, and digitally equipped consultation rooms and reception areas.

NACO is a co-investment fund for start-ups and small and medium-sized businesses (SMEs). NACO is a regional co-investment fund backed by Région Nouvelle-Aquitaine and managed by M/Capital Partners.

Investment focus

Health Care, Medical, Manufacturing
Seed, Series A, Funding Round
France

Portfolio highlights

inHEART — inHEART is a spin-off from IHU Liryc and Inria, two top-tier research centers respectively in cardiac electrophysiology and digital science and technology, that develops software solutions for medical image analysis and cardiac modeling in heart rhythm disorders. inHEART vision is to make the bridge between radiology and cardiology to become aworldwide leader in image-guided diagnosis, therapy planning and navigation software solutions for heart rhythm disorders.
Pony — Instant city bike hire
Touch Sensity — Touch Sensity is an information technology company that specializes in the fields of IoT and sensors.

Credit Mutuel is a French investment bank specialized in early stage venture investments.

Investment focus

Finance, Financial Services, E-Commerce
Funding Round, Series A, Seed
France

Portfolio highlights

Hipli — Hipli is a reusable, eco-friendly packaging solution that offers a sustainable alternative to plastic packaging for e-commerce businesses.
Vinidaily — Vinidaily is the application that helps you choose the wine 100% adapted to your tastes and the occasion, in your favorite supermarket and soon everywhere else.
Agrilife Studio — Agrilife Studio is a startup studio focuses on agriculture and environment.

Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, France

Portfolio highlights

VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
LEXEO Therapeutics — LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (singlegenemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.

IRDI Gestion aims to participate in the economic growth and job creation in their regions. For this, their teams create a real partnership with the companies they accompany, based on a relationship of trust and proximity.IRDI Gestion currently manages €150 million and has financial tools able to accompany the Southwest SMEs in the creationphase, development or transmission, with intervention tickets from equity € 100000 to € 5000000.Precursor of regional investment capital of the Southwest, with a presence of over 35 years, the IRDI Group consists of 3 SCR:- IRDI, created in 1981 to foster industrial growth companies based in the South West of France- MPcroissance, created in 1996 to assist small businesses in Midi-Pyrénées- IRDInov, created in 2012 under the leadership of the National Seed Fund (under the PIA) to fund the initiation of innovative companiesIn 2015, the management company IRDI Gestion, approved by the AMF, was formed to structure the group and bring new development projects.

Investment focus

Health Care, Biotechnology, Software
Funding Round, Series A, Series B
France

Portfolio highlights

REEV — REEV motorizes medical orthoses to help millions of people affected by gait disorders to walk, stand, sit and climb stairs with greater ease every day.
Starfish Bioscience — STARFISH Bioscience focuses on the creation and development of microbiological solutions for agriculture and vineyards. Our objective is to regenerate soils by restoring their microbiomes, increasing sustainability and productivity while minimizing environmental impact. We are dedicated to improving humanity's well-being and preserving theearth by inventing technologies that address the future difficulties of global agriculture.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.